BioEclipse Therapeutics, Inc

BioEclipse Therapeutics is participating in the BIOJPM Partnering week Jan 13-16 2025. We will be showcasing our ovarian cancer data from 16 patients treated in our basket trial phase 1 study with CRX100 with single infusions, two infusions and two infusions combined with a checkpoint inhibitor. Our CEO will also discuss our translational data supporting the unique mechanism of action for CRX100 compared to other cell therapies and our manufacturing strategies. Look forward to seeing my colleagues at the conference.

?????? ???????????????? ??????-???????????????????? ?????? & ?????? ????????????: ???????????? ???? ?????????? ???????????????? ?? ???????? ????????????: https://lnkd.in/gCSTBBJP Exciting developments in the ??????-???????????????????? ?????? & ?????? ????????????! As biopharmaceutical demand continues to surge, the CMO and CRO sectors are evolving rapidly. ???????????? ????????????: The global CMO and CRO market is projected to grow significantly, driven by increasing R&D activities and the need for innovative therapies. ?????? ????????????: ??????????????????????: Companies are increasingly outsourcing production and research to streamline processes and reduce costs. ?????????????????????????? ????????????????????????: Adoption of automation and AI is enhancing efficiency and accuracy in bio-production. ???????????????????????????? ??????????: Growing emphasis on sustainable practices and green biomanufacturing. ?????????????????????????? ??????????: The rise in personalized medicine and biologics opens new avenues for CMOs and CROs to expand their services and capabilities. ?????? ??????????????: CERBA HEALTHCARE BioEclipse Therapeutics, Inc Lonza Boehringer Ingelheim FUJIFILM Diosynth Biotechnologies Samsung Biologics AbbVie Almac Group ? Inno Biologics Sdn Bhd Toyobo U.S.A., Inc. ???????????? ???????? ????????????: https://lnkd.in/gFaGwkjQ Let’s connect to discuss the future of bio-production and how these trends will shape our industry! #bioproduction #cmo #cro #biopharma #innovation #marketresearch #markettrends #marketanalysis #globallindustry

?? Join the Conversation on the Future of Cancer Treatment! Are you passionate about advancing cancer therapies? Don't miss the upcoming roundtable discussion on "Development of Multiplex Technologies to Develop Combination Drug Strategies" happening on September 24th, 2024, from 16:30 - 17:30 on the Tumor Microenvironment (TME) Track at the Immuno-Oncology Xchange - San Francisco. SECURE YOUR FREE PASS TODAY! https://lnkd.in/etJcbt75 ??? Key Topics: ?? Induction of checkpoints and other components of tumor immunity ?? Breaching the Tumor Microenvironment (TME) ?? Tumor cell killing and other surrogates for overall survival ?? We are thrilled to have Pamela Contag, CEO of BioEclipse Therapeutics, Inc as our industry expert leading this discussion. Dr. Contag is a recognized leader in the field with a remarkable track record, including leading BioEclipse Therapeutics into a phase 1 clinical trial with a combination drug for therapy-refractory solid tumors. Her extensive experience and numerous accolades, including being named one of the "Top 25 Women in Small Business" by Fortune magazine, make her insights invaluable. This is a unique opportunity to gain insights from a pioneer in the industry and engage in a lively discussion on the cutting edge of cancer treatment. ?? Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. ?? #ImmunoOncologyXchange #CancerResearch #BioEclipseTherapeutics #TumorMicroenvironment #CancerTherapies #LifeSciences #Biotech #Pharma #Oncology #SanFranciscoEvents #Pharmaceuticals #DrugDevelopment #ClinicalTrials #Biotechnology #MedicalResearch #OncologyResearch #Immunotherapy #PrecisionMedicine #BiotechInnovation #HealthcareInnovation #LifeScienceLeaders #TME #BioEclipse #SanFranciscoBiotech #WomenInSTEM #Entrepreneurship #BiotechLeadership #HealthTech #ScientificCommunity #InnovationInHealthcare #R&D #OncologyResearch #hubxchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Oncolytic virus therapies using the vaccinia virus offer a promising strategy for cancer treatment by exploiting the virus's ability to specifically infect and destroy cancer cells. Originally utilized in the smallpox vaccine, the vaccinia virus has been modified to function as an oncolytic virus due to its strong replication capacity and its ability to provoke robust immune responses. These engineered viruses can be tailored to selectively target tumor cells while sparing healthy tissues, and they can be equipped with therapeutic genes to boost their anticancer effects. The virus's replication inside tumor cells leads to their destruction, which not only directly kills the cancer cells but also activates the immune system to recognize and attack the tumor. Currently, several companies, including Genelux Corporation, SillaJen, BioInvent International AB, BioEclipse Therapeutics, Inc, Transgene, VacV Biotherapeutics, and others, are developing vaccinia virus oncolytic therapies at various stages of development. Explore the most promising vaccinia virus-based oncolytic virus therapies in the pipeline at https://lnkd.in/gFxHCwiX

hubXchange was a great experience last year and I am pleased to join in the discussion again. Looking forward to seeing everyone there.

Oncolytic virus therapy represents a promising and evolving field in cancer treatment with the potential to address a wide range of indications. These indications include solid tumors such as melanoma, brain cancer, and pancreatic cancer, as well as breast cancer, lung cancer, bone cancer, head and neck cancer, and several others. The success of oncolytic virus therapy in these contexts is attributed to its ability to specifically infect and lyse cancer cells, stimulate anti-tumor immune responses, and overcome conventional treatment limitations. Many pharma companies such as Akamis Bio, Amgen, AmunBio, Inc, Apices Soluciones, Beijing Bio-Targeting Therapeutics Technology Co., Ltd, BioEclipse Therapeutics, Inc, BioInvent International AB, BullFrog AI, Calidi Biotherapeutics, Candel Therapeutics, CG Oncology, Codagenix Inc., Daiichi Sankyo US, DNAtrix, EpicentRx, Inc., Genelux, GeneMedicine, Hangzhou Converd Co., Ltd., ImmVira Pharma, Imugene Limited, Istari Oncology, Lokon Pharma AB, Memgen, Inc., Mustang Bio, Nouscom , Oncolys BioPharma Inc., Oncolytics Biotech Inc., ORCA Therapeutics, Oryx GmbH, PrimeVax Immuno-Oncology, Replimune, Shanghai Sunway Biotech Co. Ltd., Shanghai Yuansong Biotechnology, Shanghai Yunying Medical Technology, SillaJen, Sorrento Therapeutics, Inc., Surv BioPharma Inc., Takara Bio USA, Inc., Theolytics, Theriva Biologics, Inc., TILT Biotherapeutics Ltd, Transgene, Treovir Inc., VacV Biotherapeutics, Valo Therapeutics Ltd, Vaxiion Therapeutics, Virogin Biotech, Vyriad, and other are currently working with their lead assets to treat several cancers. Dive deep and get a detailed assessment of the top 15 indications for oncolytic virus therapy at: https://lnkd.in/gXvWRKuU

Okay, let's see if we can do this: It is my full intent to share my learned experiences! The end of our 1st week LA BioStart Bioscience Entrepreneurs Bootcamp with LA BioSpace included powerful discussions on Leadership Journeys, the State of the Bioscience Ecosystem in Los Angeles, and Strategic Discussions with Investors. We also endured the 'No Pain Pitch Session' where I got to learn more about the entrepreneurs in my cohort and their upcoming Bioscience endeavors. I will be tagging their LinkedIn company page as they grow. Check 'em out! They're eager and ready for the industry! Featured Leadership Journeys: Brenda A. McCabe, MBA, Will Clodfelter, Sumant Ramachandra, M.D., Ph.D. Featured Bioscience in LA Ecosystem Experts: Howard Kozloff, Rohit Shukla, Lacarya Scott, CFA, and Stephen Cheung with moderation by Stephanie Hsieh. Featured Investment Strategists: Pamela Contag, Stan Tomsic, Min-Yi Shih, Gregg A. Klang, and John Chi. More to come next week! Howard Xu with LA BioSpace, Next Act Advisors, Ponto Ventures, LLC, ImmPACT Bio, BioscienceLA, Los Angeles County Economic Development Corporation (LAEDC), Tungsten Advisors, Noblespace, Larta Institute, BioEclipse Therapeutics, Inc, Pasadena Angels, TCA Los Angeles, Synova Life Sciences, and Cern Device

We have been made aware that a fake BioEclipse email address is being used to offer applicants jobs with our company. Please double check that any communications from BioEclipse Therapeutics, Inc come from an email address with the domain @bioeclipse.com. We are not currently hiring or interviewing for any administrative positions. Best of luck in your job search!

BioEclipse Therapeutics, Inc continues to rank in the 5 Top Pharma Startups Tackling Ovarian Cancer by StartUs Insights! https://lnkd.in/gDafMCr9 #oncology #ovariancancer #CRX100

Oliver Dorigo, MD, PhD, discusses the investigation of BioEclipse Therapeutics, Inc’s CRX100 in patients with recurrent, platinum-resistant ovarian cancer. https://lnkd.in/gAvePMG3